Literature DB >> 22425930

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

Jamie E Chaft1, Natasha Rekhtman, Marc Ladanyi, Gregory J Riely.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22425930      PMCID： PMC3690308          DOI： 10.1097/JTO.0b013e31824c9485

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Authors:  Akihiko Yoshida; Koji Tsuta; Harumi Nakamura; Takashi Kohno; Fumiaki Takahashi; Hisao Asamura; Ikuo Sekine; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Hitoshi Tsuda
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

2.  ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

Authors:  Samuel J Klempner; David W Cohen; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

3.  Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.

Authors:  Naobumi Tochigi; Sanja Dacic; Marina Nikiforova; Kathleen M Cieply; Samuel A Yousem
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

4.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

5.  Clinicopathologic characteristics of adenosquamous carcinoma of the lung.

Authors:  S Takamori; M Noguchi; S Morinaga; T Goya; S Tsugane; T Kakegawa; Y Shimosato
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860
  5 in total
  13 in total

Review 1.  Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.

Authors:  Bo Zhang; Yanwei Zhang; Jianlin Xu; Xueyan Zhang; Tianqing Chu; Shuyuan Wang; Jie Qian; Rong Qiao; Jun Lu; Lele Zhang; Baohui Han
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

2.  ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.

Authors:  Hyojin Kim; Eunhyang Park; Yu Jung Kim; Jin-Haeng Chung
Journal:  Virchows Arch       Date:  2013-04-21       Impact factor: 4.064

3.  First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.

Authors:  Omid Savari; Jason C Chang; Justin A Bishop; Muthu Kumar Sakthivel; Frederic B Askin; Natasha Rekhtman
Journal:  J Thorac Oncol       Date:  2022-06-28       Impact factor: 20.121

4.  Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Authors:  Matthew D Hellmann; Jamie E Chaft; Valerie Rusch; Michelle S Ginsberg; David J Finley; Mark G Kris; Katharine A R Price; Christopher G Azzoli; Matthew G Fury; Gregory J Riely; Lee M Krug; Robert J Downey; Manjit S Bains; Camelia S Sima; Nabil Rizk; William D Travis; Naiyer A Rizvi; Paul K Paik
Journal:  Cancer Chemother Pharmacol       Date:  2013-06-28       Impact factor: 3.333

5.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

6.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

7.  Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Authors:  Todd Hembrough; Wei-Li Liao; Christopher P Hartley; Patrick C Ma; Vamsidhar Velcheti; Christopher Lanigan; Sheeno Thyparambil; Eunkyung An; Manish Monga; David Krizman; Jon Burrows; Laura J Tafe
Journal:  Clin Chem       Date:  2015-11-19       Impact factor: 8.327

8.  Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.

Authors:  Federica Zito Marino; Federica Zito Marino; Giuseppina Liguori; Gabriella Aquino; Elvira La Mantia; Silvano Bosari; Stefano Ferrero; Lorenzo Rosso; Gabriella Gaudioso; Nicla De Rosa; Marianna Scrima; Nicola Martucci; Antonello La Rocca; Nicola Normanno; Alessandro Morabito; Gaetano Rocco; Gerardo Botti; Renato Franco
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

9.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

10.  Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report.

Authors:  Wenxian Wang; Zhengbo Song; Yiping Zhang
Journal:  Thorac Cancer       Date:  2015-07-29       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.